232 related articles for article (PubMed ID: 33299547)
1. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry.
Music M; Iafolla M; Soosaipillai A; Batruch I; Prassas I; Pintilie M; Hansen AR; Bedard PL; Lheureux S; Spreafico A; Razak AA; Siu LL; Diamandis EP
F1000Res; 2020; 9():337. PubMed ID: 33299547
[No Abstract] [Full Text] [Related]
2. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
3. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
[TBL] [Abstract][Full Text] [Related]
4. Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation.
Thomas D; Liakos V; Vassiliou E; Hatzimarkou F; Tsatsoulis A; Kaldrimides P
J Endocrinol Invest; 2007 Mar; 30(3):173-80. PubMed ID: 17505148
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of chemiluminescence immunoassays for detecting thyroglobulin (Tg) and thyroid peroxidase (TPO) autoantibodies using the IMMULITE 2000 system.
Bohuslavizki KH; vom Baur E; Weger B; Krebs C; Saller B; Wetlitzky O; Musiol N; Kühnel W; Lambrecht HG; Clausen M
Clin Lab; 2000; 46(1-2):23-31. PubMed ID: 10745978
[TBL] [Abstract][Full Text] [Related]
6. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
7. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
9. The quantitative measurement of autoantibodies to thyroglobulin and thyroid peroxidase by automated microparticle based immunoassays in Hashimoto's disease, Graves' disease and a follow-up study on postpartum thyroid disease.
Gilmour J; Brownlee Y; Foster P; Geekie C; Kelly P; Robertson S; Wade E; Braun HB; Staub U; Michel G; Lazarus JH; Parkes AB
Clin Lab; 2000; 46(1-2):57-61. PubMed ID: 10745983
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab.
Eun Y; Kim IY; Sun JM; Lee J; Cha HS; Koh EM; Kim H; Lee J
Sci Rep; 2019 Oct; 9(1):14039. PubMed ID: 31575933
[TBL] [Abstract][Full Text] [Related]
11. Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency.
Pedersen IB; Knudsen N; Jørgensen T; Perrild H; Ovesen L; Laurberg P
Clin Endocrinol (Oxf); 2003 Jan; 58(1):36-42. PubMed ID: 12519410
[TBL] [Abstract][Full Text] [Related]
12. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
13. Serum Detection of Anti-thyroid Peroxidase and Anti-thyroglobulin Antibodies in Chinese Patients With Pemphigus Vulgaris and Pemphigus Foliaceus and Literature Review.
Wang HX; Yang Y; Hu JY; Zhang LM; Cai YF; Guo H; Xiao T; Chen HD; Gao XH; Qiao S
Front Immunol; 2021; 12():653356. PubMed ID: 33796116
[TBL] [Abstract][Full Text] [Related]
14. Establishing thresholds and effects of gender, age, and season for thyroglobulin and thyroid peroxidase antibodies by mining real-world big data.
Ma C; Li D; Yin Y; Wu J; Guo X; Zhang R; Hu Y; Zou Y; Li W; Wang D; Cheng X; Qiu L
Clin Biochem; 2019 Dec; 74():36-41. PubMed ID: 31476287
[TBL] [Abstract][Full Text] [Related]
15. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
17. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
19. [The association between baseline TPOAb and/or TgAb positivity and thyroid immune-related adverse events in patients with malignancies following treatment with immune checkpoint inhibitors].
Gao Y; Ye T; Wu LG; Xu Y; Wang X; Cheng XQ; Zhang YL; Wang YY; Fan XR; Zhao HT; Liu H; Chai XF; Zhang L; Wang MZ; Li NS; Lian XL
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(12):963-969. PubMed ID: 38514346
[No Abstract] [Full Text] [Related]
20. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
